<DOC>
	<DOCNO>NCT01478308</DOCNO>
	<brief_summary>This study conduct determine effectiveness standard 3 weekly treatment use docetaxel prednisone metformin patient castration-resistant metastatic prostate cancer . It also conduct determine level toxicity metformin add every 3 weekly docetaxel treatment patient endocrine resistent , metastatic prostate cancer .</brief_summary>
	<brief_title>Metformin With Standard Taxotere Prednisone Treatment Castration Resistant Prostate Cancer</brief_title>
	<detailed_description>This single-arm , non-randomized Phase II trial docetaxel give every 3 week metformin twice daily Prednisone twice daily . The study duration trial open end . The patient would take metformin long treat docetaxel .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>All patient , 18 age old , hormone refractory prostate cancer eligible . Patients must life expectancy least 12 week . Patients must Zubrod performance status 02 . Patients must sign informed consent . Patients adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500 cells/mm3 platelet count &gt; 100,000/mm3 absence regular red blood cell transfusion requirement . Patients adequate hepatic function total bilirubin &lt; 2 mg/dl SGOT SGPT &lt; two time upper limit normal , adequate renal function define serum creatinine &lt; 1.5 x upper limit normal . Patients must pathologically confirm prostate cancer PSA increase despite androgen deprivation therapy . Diabetic patient therapy Metformin eligible provide Metformin dose least 850mg twice daily . Patients symptomatic brain metastasis exclude study . Patients insulin eligible . Patients may receive concurrent chemotherapy radiation therapy trial . Patients severe medical problem uncontrolled diabetes mellitus , cardiovascular disease , congestive heart failure define New York Heart Association Class III IV , hepatic dysfunction , active infection eligible trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>prostate</keyword>
	<keyword>castration resistant</keyword>
	<keyword>hormone resistant</keyword>
	<keyword>CRPC</keyword>
</DOC>